Inhibrx Wins CARB-X Award Of Up To $6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections

Tuesday, October 31, 2017 Alternative Medicine News
Email Print This Page Comment bookmark
Font : A-A+

-Award provides non-dilutive funding to advance INBRX-111, discovered using Inhibrx's best-in-class discovery engine, through Phase 1-

LA JOLLA, Calif., Oct. 31, 2017 /PRNewswire/ -- Inhibrx, a clinical stage biologic therapeutic company using proprietary

single domain antibody platforms to develop multispecific and multivalent therapeutics for oncology, infectious disease and inflammatory conditions, announced today a significant collaboration with CARB-X, (Combating Antibiotic Resistant Bacteria Accelerator), the world's largest public-private partnership focused on funding the advancement of products to treat drug-resistant bacteria.  CARB-X selected Inhibrx from among 202 applications received from researchers around the globe.  Inhibrx will receive an initial award of up to $4.55M and potentially up to $1.49M more from CARB-X based on the achievement of certain milestones related to the advancement of INBRX-111. 

CARB-X is funded by its global partners including BARDA, Wellcome Trust and NIAID to advance promising antibiotic candidates, including INBRX-111, through the early stages of development.

"The Inhibrx project enriches the diversity of the CARB-X pipeline with an approach that has the potential to prevent or treat drug-resistant infections, like Pseudomonas, and save lives," said Kevin Outterson, Executive Director of CARB-X, the world's leading non-profit partnership dedicated to accelerating the development of antibiotics, vaccines, diagnostics and other products to treat drug-resistant bacterial infections. "The projects in the Powered by CARB-X portfolio are in the early stages of research, and there is always a high risk of failure. But if successful, these projects, including Inhibrx's antibody project, hold exciting potential in the fight against the deadliest antibiotic-resistant bacteria."

"The need for new therapeutics to solve the antibiotic resistance epidemic is urgent as well as the need for novel funding mechanisms to support research, development and commercialization," said Mark Lappe, CEO of Inhibrx. "Inhibrx is committed to addressing the global health threat of antibiotic resistance with multiple efforts addressing priority list pathogens.  With this non-dilutive award from CARB-X, we look forward to rapidly advancing INBRX-111 through Phase 1 with the goal of providing a novel option for patients with or at high risk for drug-resistant Pseudomonas infections."

INBRX-111 is a multi-specific and multi-epitopic anti-virulence/opsonizing biotherapeutic targeting Pseudomonas, a difficult-to-treat Gram-negative bacterial pathogen.  Through its novel mechanism of action, INBRX-111 has the potential to be a best-in-class anti-Pseudomonas antibody for both curative and preventative therapies with broad strain specificity and excellent in vivo efficacy.

About Inhibrx

Inhibrx is a privately-held, clinical stage biologic therapeutic company focused on the treatment of oncology, infectious disease and inflammatory conditions.  Inhibrx's proprietary platforms and technologies enable fit-for-function biotherapeutics that optimally interface with the biology of each target antigen, focus immune activation and mediate enhanced signaling.  Therapeutic proteins include multispecific and multivalent molecules designed using our composite modular single domain antibody technology.  Inhibrx's lead program in the infectious disease space is INBRX-111, a multi-specific and multi-epitopic anti-virulence/opsonizing antibody targeting Pseudomonas that has the potential to be a best-in-class antibody with broad strain specificity and excellent in vivo efficacy.

About CARB-X

CARB-X is the world's largest public-private partnership devoted to antibacterial preclinical R&D.  Funded by BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing $455 million from 2016-2021 to support innovative antibiotics, vaccines and rapid diagnostics moving towards human clinical trials.  CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives.  CARB-X is led by Boston University School of Law.  Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit and follow us on Twitter @CARB_X. 

Inhibrx Media Contact:

Amy ConradJuniper 858-366-3243


View original content:

SOURCE Inhibrx


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store